Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Gränges in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin)
Mandate

Vinge has advised Gränges in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin)

December 08, 2020 EU, Competition and Regulatory

Vinge has advised Gränges AB (publ) in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin).

The concentration was notified to, inter alia, the European Commission. After a thorough pre-nonfiction phase and formal review, which included several market contacts, the concentration, which results in a combination of the parties’ production of flat rolled aluminium products in the EU, was unconditionally approved by the European Commission after a phase 1 review on the 23 September 2020.

The decision is available at:  https://ec.europa.eu/competition/mergers/cases1/202050/m9560_488_3.pdf

Vinge’s team consisted mainly of Pär Remnelid, Johan Wahlbom and Julia Söderdahl.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025